PeterJ.McAllisterMD

Medical Director at the New England Institute For Neurology & Headache and Assistant Professor of Internal Medicine, at The Frank H. Netter School of Medicine at Quinnipiac University

Join to view full profile

Dr. McAllister is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. McAllister's full profile

Already have an account?

Office
75 Kings Highway Cutoff
Fairfield, CT 06824
Phone+1 203-333-1133

Fax+1 203-914-1907

Education & Training

Virginia Commonwealth University Health SystemResidency, Neurology, 1992 - 1996
Virginia Commonwealth University Health SystemInternship, Internal Medicine, 1991 - 1992
Uconn School Of MedicineClass of 1991

Certifications & Licensure

CT State Medical License 1996 - 2025
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

Board Member Brain Injury Alliance of Connecticut
Board Member Headache Cooperative of New England
Top Doctors: New York Metro Area Castle Connolly, 2010-2014
Greenwich Magazine Castle Connolly, 2010, 2013-2014
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Most Compassionate Doctor American Registry
Top MD Consumers Checkbook
Join now to see all

Clinical Trials

A Study of Galcanezumab (LY2951742) in Participants With Migraine Headache Start of enrollment: 2014 Jul 07
Completed
Phase 2
A Study of Galcanezumab in Participants With Chronic Cluster Headache Start of enrollment: 2015 Jun 18
Completed
Phase 3
Acute Treatment of Migraine With e-TNS Start of enrollment: 2016 Feb 01
Completed
Not Applicable
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease Start of enrollment: 2016 Jun 01
Terminated
Phase 3
Efficacy and Safety of Tx360® Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine Start of enrollment: 2017 Sep 20
Completed
Phase 3
Roles: Contact
Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease Start of enrollment: 2021 Nov 18
Active, not recruiting
Phase 3
Roles: Contact, Principal Investigator
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type Start of enrollment: 2022 Nov 01
Recruiting
Phase 3
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

4 citations
Effects on walking of simultaneous upper/lower limb abobotulinumtoxina injections in patients with stroke or brain injury with spastic hemiparesis.
Peter McAllister, Svetlana Khatkova, Steven G Faux, Philippe Picaut, Romain Raymond
Journal of Rehabilitation Medicine. 2019-10-29
4 citations
Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis.
Cristina Tassorelli, Kateryna Onishchenko, Rashmi B Halker Singh, Molly Duan, Laure Dupont-Benjamin
Cephalalgia. 2024-02-01
20 citations
Cell Therapy for Chronic TBI: Interim Analysis of the Randomized Controlled STEMTRA Trial.
Masahito Kawabori, Alan Weintraub, Hideaki Imai, Laroslav Zinkevych, Peter McAllister
Neurology. 2021-01-04

Press Mentions

U.S. FDA Approves QULIPTA® (Atogepant) for Adults with Chronic MigraineApril 17th, 2023
Scilex Holding Company, a Majority-Owned Subsidiary of Sorrento Therapeutics, Inc., Acquires Rights to FDA-Approved ELYXYB™ in the U.S. And Canada for the Acute Treatment of MigraineFebruary 12th, 2023
Race, Ethnicity, and Socioeconomics Are Often Barriers to Migraine CareMay 14th, 2021
Join now to see all